FY2025 · period end Dec '25 · from the 10-K filed Mar 23, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.53B | $0.52B | $0.51B | $0.49B | $0.47B |
| Gross Profit | $0.11B | $0.10B | $0.11B | $0.10B | — |
| Operating Income | $0.06B | $0.06B | $0.05B | $0.04B | $0.05B |
| Net Income | $0.03B | $0.03B | $0.04B | $0.02B | $0.02B |
| EPS (Diluted) | $0.63 | $0.66 | $0.77 | $0.42 | $0.42 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.58B | $0.59B | $0.59B | $0.58B | $0.58B |
| Total Liabilities | — | — | — | — | — |
| Stockholders' Equity | $0.27B | $0.25B | $0.22B | $0.18B | $0.16B |
| Cash & Equivalents | $0.02B | $0.02B | $0.02B | $0.02B | — |
| Total Debt | $0.11B | $0.13B | $0.16B | $0.17B | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.04B | $0.06B | $0.02B | $0.02B | $0.04B |
| Capital Expenditures | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Free Cash Flow | $0.03B | $0.04B | $0.01B | $0.01B | $0.02B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 20.7% | 19.7% | 21.5% | 19.6% | — |
| Operating Margin | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| Net Margin | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% |
| Return on Equity | 11.3% | 13.2% | 18.0% | 11.3% | 12.3% |
| Return on Assets | 5.1% | 5.4% | 6.3% | 3.4% | 3.4% |
| Debt / Equity | 0.41× | 0.50× | 0.73× | 0.94× | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001193125-26-326345 | Jun 30, 2026 | Jul 30, 2026 | Jul 30, 2026 21:13 UTC | EDGAR |
| 8-K | 0001193125-26-324101 | Jul 29, 2026 | Jul 29, 2026 | Jul 29, 2026 20:43 UTC | EDGAR |
| 8-K | 0001193125-26-221857 | May 12, 2026 | May 13, 2026 | May 13, 2026 20:54 UTC | EDGAR |
| 10-Q | 0001193125-26-198109 | Mar 31, 2026 | May 1, 2026 | Apr 30, 2026 22:03 UTC | EDGAR |
| 8-K | 0001193125-26-192018 | Apr 29, 2026 | Apr 29, 2026 | Apr 29, 2026 20:43 UTC | EDGAR |
| 8-K | 0001193125-26-119934 | Mar 23, 2026 | Mar 23, 2026 | Mar 23, 2026 20:59 UTC | EDGAR |
| 10-K | 0001193125-26-118177 | Dec 31, 2025 | Mar 23, 2026 | Mar 21, 2026 01:54 UTC | EDGAR |
| 8-K | 0001193125-26-093962 | Feb 27, 2026 | Mar 5, 2026 | Mar 5, 2026 21:11 UTC | EDGAR |
Direct links to SEC EDGAR. CLB has additional filings available on the SEC site.
6 numbers Core Laboratories Inc. /DE/ later changed — same XBRL tag, both filings linked.
Stockholders' Equity Attributable to Parent·As of Dec 31, 2024
Notable restatementwas$252M
Revised down in a 10-K.
Assets·As of Dec 31, 2024
Minor restatementwas$590.4M
Revised down in a 10-K.
Assets·As of Mar 31, 2025
Minor restatementwas$591.5M
Revised down in a 10-Q.
Assets·As of Jun 30, 2025
Minor restatementwas$602.1M
Revised down in a 10-Q.
Liabilities, Current·As of Dec 31, 2024
Notable restatementwas$97.6M
Revised up in a 10-K.
Assets, Current·As of Dec 31, 2024
Notable restatementwas$226.6M
Revised down in a 10-K.
CLB is not the only one.
See every restatement we've found across the market — or get an alert the next time CLB revises a number.
Restatements are detected by comparing every vintage of a fact across all of Core Laboratories Inc. /DE/'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows CLB's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Core Laboratories Inc. /DE/ — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on CLB yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on CLB and publish the result to your public profile.
Ask about Core Laboratories Inc. /DE/
Continue in Workspace — cited answers on CLB, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs